Legal & General Group PLC Aeglea Bio Therapeutics, Inc. Transaction History

Legal & General Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.81 $1,240 - $2,643	-3,264 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$6.32 - $8.38 $9,536 - $12,645	-1,509 Reduced 31.62%	3,264 $23,000
Q1 2021 May 17, 2021	SELL	$6.76 - $8.57 $703 - $891	-104 Reduced 2.13%	4,773 $38,000
Q3 2020 Nov 13, 2020	SELL	$6.51 - $9.33 $11,672 - $16,728	-1,793 Reduced 26.88%	4,877 $35,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $12,366 - $34,047	3,084 Added 86.0%	6,670 $62,000
Q1 2020 May 14, 2020	SELL	$3.51 - $8.48 $4,250 - $10,269	-1,211 Reduced 25.24%	3,586 $17,000
Q4 2019 Feb 13, 2020	BUY	$7.23 - $8.55 $983 - $1,162	136 Added 2.92%	4,797 $37,000
Q2 2019 Aug 14, 2019	BUY	$6.1 - $8.78 $7,747 - $11,150	1,270 Added 37.45%	4,661 $30,000
Q1 2019 May 15, 2019	BUY	$7.6 - $9.4 $7,318 - $9,052	963 Added 39.66%	3,391 $27,000
Q2 2018 Aug 10, 2018	BUY	$7.87 - $10.89 $19,108 - $26,440	2,428 New	2,428 $26,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.